Making top-quality cancer care accessible to all.100% free, no account required.

Studying Y90 Therapy to Improve Liver Cancer Surgery Outcomes

NCT04390724 · Recruiting
About this trial

This trial looks at how to use Y90 radioembolization to help people with liver cancer. The goal is to grow the liver enough so that patients can safely have surgery to remove tumors. There are two groups in the study. One group will receive the standard treatment, and the other group will get a specially determined dose based on the first group's results. This research might help future patients needing liver surgery.

Locations and contact

This trial is running at 2 locations in the United States. 1 of them are currently recruiting.

United States2 locations · 1 recruiting
  • Northwestern UniversityChicago, IllinoisRecruiting
  • Mayo ClinicJacksonville, FloridaActive Not Recruiting
Who to ask about joining
Who can join

This study is open to adults aged 18 and older, both men and women, who have been diagnosed with liver cancer. Participants must have a specific liver condition and be willing to take part in the study. Some patients may not qualify due to other health issues or if they are pregnant. The trial team will confirm eligibility for each participant.

What happens during the trial

Participants will be divided into two groups. The first group will receive the standard Y90 treatment. The second group will receive a treatment based on the best dose found in the first group. Everyone will receive Y90 radioembolization, which involves using tiny radioactive beads to treat the cancer. Some participants may also have additional tests like blood draws and MRIs to monitor their progress.

The trial team

The trial is led by Northwestern University, with collaboration from the Mayo Clinic. Dr. Robert Lewandowski and Dr. Jeremy Collins are the principal investigators in charge of the study.

Important dates

The trial started on July 17, 2020, and is expected to finish by July 2026. It is currently enrolling new participants.

Additional information

The trial's ID is NCT04390724. It is an observational study, which means it looks at how well the treatment works and its safety. This trial is not regulated by the FDA for drugs, but it is for devices, and it aims to include 104 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals